FY2025 EPS Estimates for Vericel Reduced by HC Wainwright

Vericel Co. (NASDAQ:VCEL) – Analysts at HC Wainwright lowered their FY2025 earnings estimates for Vericel in a note issued to investors on Friday, February 28th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.26 per share for the year, down from their prior forecast of $0.35. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. HC Wainwright also issued estimates for Vericel’s FY2027 earnings at $1.18 EPS, FY2028 earnings at $1.93 EPS and FY2029 earnings at $2.66 EPS.

Other analysts have also issued reports about the stock. Stephens reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. BTIG Research upped their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Canaccord Genuity Group upped their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Truist Financial reiterated a “buy” rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday. Finally, StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $62.29.

Vericel Price Performance

NASDAQ:VCEL opened at $51.14 on Monday. Vericel has a 1-year low of $39.12 and a 1-year high of $63.00. The company has a 50-day moving average of $56.93 and a 200 day moving average of $51.93. The firm has a market cap of $2.52 billion, a PE ratio of 852.48 and a beta of 1.72.

Hedge Funds Weigh In On Vericel

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in Vericel by 214.0% in the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock worth $24,837,000 after buying an additional 400,667 shares during the period. Stifel Financial Corp increased its holdings in Vericel by 40.0% in the 3rd quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company’s stock worth $1,186,000 after buying an additional 8,020 shares during the period. Geode Capital Management LLC increased its holdings in Vericel by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock worth $48,768,000 after buying an additional 9,613 shares during the period. Louisiana State Employees Retirement System increased its holdings in Vericel by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock worth $1,312,000 after buying an additional 200 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Vericel in the 3rd quarter worth approximately $563,000.

Insiders Place Their Bets

In other news, insider Jonathan Siegal sold 3,908 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the transaction, the insider now owns 1,206 shares in the company, valued at $74,759.94. This represents a 76.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,500 shares of company stock worth $466,200. 5.20% of the stock is owned by corporate insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.